Is Paritaprevir compatible with breastfeeding? Do we have alternatives for Paritaprevir?

Paritaprevir

August 6, 2017 (Low Risk)

Used in the treatment of hepatitis C, usually in combination with other antivirals.

Since the last update we have not found published data on its excretion in breast milk.

Its pharmacokinetic data (slightly elevated molecular weight and very high percentage of plasma protein binding) make it very unlikely that significant amounts will pass into milk, so that although there is disagreement (Thompson 2016, Spera 2016), other experts believe that treatment with Paritaprevir, on its own or in combination with Ombitasvir and ritonavir or with Ombitasvir, Ritonavir and Desabuvir is not contraindicated during breastfeeding (LactMed 2016).


See below the information of these related products:

Alternatives

We do not have alternatives for Paritaprevir.

Very Low Risk

Compatible. Not risky for breastfeeding or infant.

Low Risk

Moderately safe. Mild risk possible. Follow up recommended. Read the Comment.

High Risk

Poorly safe. Evaluate carefully. Use a safer alternative. Read the Comment.

Very High Risk

Not recommended. Cessation of breastfeeding or alternative.

Writings

  • باريتابريفير (Arabic)
  • Паритапревир (Cyrillic)
  • C40H43N7O7S (Molecular formula)

Drug trade names

References

  1. EMA. Ombitasvir-Paritaprevir-Ritonavir. Drug Summary. 2017 Full text (in our servers)
  2. EMA. Ombitasvir-Paritaprevir-Ritonavir. Ficha técnica. 2017 Full text (in our servers)
  3. LactMed. Paritaprevir. Full Record Display. 2016 Full text (in our servers)